Cargando…

Description of a Novel Mechanism Possibly Explaining the Antiproliferative Properties of Glucocorticoids in Duchenne Muscular Dystrophy Fibroblasts Based on Glucocorticoid Receptor GR and NFAT5

Glucocorticoids are drugs of choice in Duchenne muscular dystrophy (DMD), prolonging patients’ ambulation. Their mode of action at the protein level is not completely understood. In DMD, muscle tissue is replaced by fibrotic tissue produced by fibroblasts, reducing mobility. Nuclear factor of activa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Herbelet, Sandrine, De Paepe, Boel, De Bleecker, Jan L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7731298/ https://www.ncbi.nlm.nih.gov/pubmed/33287327 http://dx.doi.org/10.3390/ijms21239225

Ejemplares similares

Abnormal NFAT5 Physiology in Duchenne Muscular Dystrophy Fibroblasts as a Putative Explanation for the Permanent Fibrosis Formation in Duchenne Muscular Dystrophy
por: Herbelet, Sandrine, et al.
Publicado: (2020)

Anti-Inflammatory and General Glucocorticoid Physiology in Skeletal Muscles Affected by Duchenne Muscular Dystrophy: Exploration of Steroid-Sparing Agents
por: Herbelet, Sandrine, et al.
Publicado: (2020)

The PKA-p38MAPK-NFAT5-Organic Osmolytes Pathway in Duchenne Muscular Dystrophy: From Essential Player in Osmotic Homeostasis, Inflammation and Skeletal Muscle Regeneration to Therapeutic Target
por: Herbelet, Sandrine, et al.
Publicado: (2021)

Cytokines and Chemokines as Regulators of Skeletal Muscle Inflammation: Presenting the Case of Duchenne Muscular Dystrophy
por: De Paepe, Boel, et al.
Publicado: (2013)

Skeletal disproportion in glucocorticoid-treated boys with Duchenne muscular dystrophy
por: Kao, Kung-Ting, et al.
Publicado: (2019)

Recent advances of glucocorticoids in the treatment of Duchenne muscular dystrophy (Review)
por: Zhang, Tianyuan, et al.
Publicado: (2021)

Disease-specific and glucocorticoid-responsive serum biomarkers for Duchenne Muscular Dystrophy
por: Hathout, Yetrib, et al.
Publicado: (2019)

The Role of Taurine in Skeletal Muscle Functioning and Its Potential as a Supportive Treatment for Duchenne Muscular Dystrophy
por: Merckx, Caroline, et al.
Publicado: (2022)

What Nutraceuticals Can Do for Duchenne Muscular Dystrophy: Lessons Learned from Amino Acid Supplementation in Mouse Models
por: De Paepe, Boel
Publicado: (2023)

Exploring the Therapeutic Potential of Ectoine in Duchenne Muscular Dystrophy: Comparison with Taurine, a Supplement with Known Beneficial Effects in the mdx Mouse
por: Merckx, Caroline, et al.
Publicado: (2022)

miR-379 links glucocorticoid treatment with mitochondrial response in Duchenne muscular dystrophy
por: Sanson, M., et al.
Publicado: (2020)

Positive effect of the combination of multilevel contracture release and glucocorticoid treatment in Duchenne muscular dystrophy
por: Weiß, Claudia, et al.
Publicado: (2020)

Growth Hormone Therapy for Children With Duchenne Muscular Dystrophy and Glucocorticoid Induced Short Stature
por: Lavi, Eran, et al.
Publicado: (2021)

Genotype characterization and delayed loss of ambulation by glucocorticoids in a large cohort of patients with Duchenne muscular dystrophy
por: Zhang, Shu, et al.
Publicado: (2021)

The role of delayed bone age in the evaluation of stature and bone health in glucocorticoid treated patients with Duchenne muscular dystrophy
por: Annexstad, E. J., et al.
Publicado: (2019)

Mechanisms and Clinical Applications of Glucocorticoid Steroids in Muscular Dystrophy
por: Quattrocelli, Mattia, et al.
Publicado: (2021)

Glucocorticoid receptor GRβ regulates glucocorticoid-induced ocular hypertension in mice
por: Patel, Gaurang C., et al.
Publicado: (2018)

Management of Adrenal Insufficiency Risk After Long-term Systemic Glucocorticoid Therapy in Duchenne Muscular Dystrophy: Clinical Practice Recommendations
por: Bowden, Sasigarn A., et al.
Publicado: (2019)

P125 The effect of glucocorticoids on rate of lung function decline in Duchenne Muscular Dystrophy patients receiving Non-Invasive Ventilation
por: Treanor, D, et al.
Publicado: (2022)

Progressive Skeletal Muscle Atrophy in Muscular Dystrophies: A Role for Toll-Like Receptor-Signaling in Disease Pathogenesis
por: De Paepe, Boel
Publicado: (2020)

Survival in Duchenne muscular dystrophy
por: RALL, SUSANNE, et al.
Publicado: (2012)

Theragnosis for Duchenne Muscular Dystrophy
por: Luce, Leonela, et al.
Publicado: (2021)

(23)Na MRI and myometry to compare eplerenone vs. glucocorticoid treatment in Duchenne dystrophy
por: A. Glemser, Philip, et al.
Publicado: (2017)

Anti-RANKL Therapy Prevents Glucocorticoid-Induced Bone Loss and Promotes Muscle Function in a Mouse Model of Duchenne Muscular Dystrophy
por: Jayash, Soher Nagi, et al.
Publicado: (2023)

Benefits of glucocorticoids in non-ambulant boys/men with Duchenne muscular dystrophy: A multicentric longitudinal study using the Performance of Upper Limb test
por: Pane, Marika, et al.
Publicado: (2015)

Hypokalemia complicating Duchenne muscular dystrophy.
por: McDonald, B., et al.
Publicado: (1987)

The role of fibrosis in Duchenne muscular dystrophy
por: KLINGLER, WERNER, et al.
Publicado: (2012)

Delay in Diagnosis of Duchenne Muscular Dystrophy
por: Rao, Vamshi K., et al.
Publicado: (2015)

Circulating Biomarkers for Duchenne Muscular Dystrophy
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2015)

Targeting angiogenesis in Duchenne muscular dystrophy
por: Podkalicka, Paulina, et al.
Publicado: (2019)

Regenerative biomarkers for Duchenne muscular dystrophy
por: Guiraud, Simon, et al.
Publicado: (2019)

Eteplirsen in the treatment of Duchenne muscular dystrophy
por: Lim, Kenji Rowel Q, et al.
Publicado: (2017)

Nutritional Challenges in Duchenne Muscular Dystrophy
por: Salera, Simona, et al.
Publicado: (2017)

Lifetime Care of Duchenne Muscular Dystrophy
por: MacKintosh, Erin W., et al.
Publicado: (2020)

The Duchenne muscular dystrophy gene and cancer
por: Jones, Leanne, et al.
Publicado: (2020)

CRISPR Therapeutics for Duchenne Muscular Dystrophy
por: Erkut, Esra, et al.
Publicado: (2022)

Exon-Skipping in Duchenne Muscular Dystrophy
por: Takeda, Shin’ichi, et al.
Publicado: (2021)

Gene Therapy for Duchenne Muscular Dystrophy
por: Elangkovan, Nertiyan, et al.
Publicado: (2021)

Family reflections: Duchenne Muscular Dystrophy
por: Gill, Omaira
Publicado: (2022)

Cardiac therapies for Duchenne muscular dystrophy
por: Shah, Md Nur Ahad, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_7mrotohk7psbpg78r09junh2ei